Equity Profile

MRNA

Moderna, Inc.

Health CareBiotechnology$18.3B

Jul31Fri

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Moderna, Inc. is a biotechnology company focused on developing mRNA-based vaccines and therapeutics....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and revenue.

N/A

Revenue Growth

Revenue growth will indicate the company's ability to generate sales, especially post-COVID vaccine demand.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

MRNA Q2-2026 Earnings Preview

Context

Company Snapshot

Moderna, Inc. is a biotechnology company focused on developing mRNA-based vaccines and therapeutics. With a market cap of $18 billion, it plays a crucial role in the health care sector, especially in the context of vaccine development and infectious disease management.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+27.75%

Avg Stock Reaction

-3.15%

Last Quarter Recap

In Q1 2026, Moderna reported an EPS of -$3.40, missing estimates by 12.58%. The stock reacted negatively, declining 1.24% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as Moderna continues to navigate post-pandemic challenges and evolving vaccine needs.

Bull Case

Investors may be optimistic if Moderna showcases strong demand for its mRNA technology and innovative pipeline, potentially leading to revenue growth.

Bear Case

Conversely, if the company fails to demonstrate a clear path to profitability or continued demand for its vaccines, investor sentiment could sour.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the projected revenue from new mRNA products?

This will indicate how well the company is diversifying its revenue streams beyond COVID-19 vaccines.

What are the plans for cost management moving forward?

Effective cost management is crucial for improving profitability, especially given the recent EPS losses.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Moderna's mRNA technology to expand into new therapeutic areas beyond COVID-19.

Supporting Evidence

The options market is pricing a 16.5% move, indicating significant uncertainty that may not align with actual performance.

Moderna's historical EPS beat rate of 75% suggests a higher likelihood of positive surprises than currently anticipated.

Key Risk

If the revenue from new mRNA products exceeds expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around Moderna's ability to pivot from pandemic-driven revenue to sustainable growth through new product offerings.

Bull Confirmed If

A revenue increase of over 15% year-over-year would confirm strong demand for Moderna's products.

Bear Confirmed If

An EPS loss greater than -$3.50 would signal ongoing profitability challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±16.5%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant move, suggesting uncertainty about the earnings report.

Options are pricing ±16.5% while MRNA has averaged ±6.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

55.7%

Calls (790K)P/C Ratio: 0.12Puts (624K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

History suggests that if Moderna beats expectations, the stock could rise by around 3.1%, confirming a positive outlook for its pipeline.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may experience a muted reaction, reflecting uncertainty.

Miss

If the company misses expectations, history suggests a potential decline of around 1.06%, which could further dampen investor sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the pipeline for new mRNA products beyond COVID-19.
2Any commentary on cost management strategies.
3Insights into market demand for vaccines and therapeutics.
4Details on partnerships or collaborations that could enhance growth.
5Guidance on expected revenue for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul28

KNSABMO

Kiniksa Pharmaceuticals International, plc

PreviewView

Jul28

CURBBMO

Company Snapshot

Moderna, Inc. is a biotechnology company focused on developing mRNA-based vaccines and therapeutics....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and revenue.

N/A

Revenue Growth

Revenue growth will indicate the company's ability to generate sales, especially post-COVID vaccine demand.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

MRNA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+27.75%

Avg Stock Reaction

-3.15%

Last Quarter Recap

In Q1 2026, Moderna reported an EPS of -$3.40, missing estimates by 12.58%. The stock reacted negatively, declining 1.24% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as Moderna continues to navigate post-pandemic challenges and evolving vaccine needs.

Bull Case

Investors may be optimistic if Moderna showcases strong demand for its mRNA technology and innovative pipeline, potentially leading to revenue growth.

Bear Case

Conversely, if the company fails to demonstrate a clear path to profitability or continued demand for its vaccines, investor sentiment could sour.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the projected revenue from new mRNA products?

This will indicate how well the company is diversifying its revenue streams beyond COVID-19 vaccines.

What are the plans for cost management moving forward?

Effective cost management is crucial for improving profitability, especially given the recent EPS losses.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Moderna's mRNA technology to expand into new therapeutic areas beyond COVID-19.

Supporting Evidence

The options market is pricing a 16.5% move, indicating significant uncertainty that may not align with actual performance.

Moderna's historical EPS beat rate of 75% suggests a higher likelihood of positive surprises than currently anticipated.

Key Risk

If the revenue from new mRNA products exceeds expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around Moderna's ability to pivot from pandemic-driven revenue to sustainable growth through new product offerings.

Bull Confirmed If

A revenue increase of over 15% year-over-year would confirm strong demand for Moderna's products.

Bear Confirmed If

An EPS loss greater than -$3.50 would signal ongoing profitability challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±16.5%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant move, suggesting uncertainty about the earnings report.

Options are pricing ±16.5% while MRNA has averaged ±6.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

55.7%

Calls (790K)P/C Ratio: 0.12Puts (624K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

History suggests that if Moderna beats expectations, the stock could rise by around 3.1%, confirming a positive outlook for its pipeline.

In-Line / Cautious

If results are in line but management provides cautious commentary, the stock may experience a muted reaction, reflecting uncertainty.

Miss

If the company misses expectations, history suggests a potential decline of around 1.06%, which could further dampen investor sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the pipeline for new mRNA products beyond COVID-19.
2Any commentary on cost management strategies.
3Insights into market demand for vaccines and therapeutics.
4Details on partnerships or collaborations that could enhance growth.
5Guidance on expected revenue for the upcoming quarters.